Donna Davis
National Patient Safety Foundation
8 Papers
11 Citations
Donna Davis is an academic researcher from National Patient Safety Foundation. The author has contributed to research in topics: Hereditary angioedema & Patient safety. The author has an hindex of 4, co-authored 8 publications.
Chat about Author
Papers
Pediatric Hereditary Angioedema Onset, Diagnostic Delay, and Disease Severity
TL;DR: Age of onset, delay in diagnosis, androgen exposure, and their influence on ultimate disease severity in a large cohort of patients with HAE highlight the importance of early HAE diagnosis and suggest the necessity of a disease management plan once the diagnosis has been made.
59
Tolerability and Effectiveness of 17-α-Alkylated Androgen Therapy for Hereditary Angioedema: A Re-examination.
TL;DR: AA therapy is usually effective for the treatment of HAE although a substantial fraction of patients with HAE do not achieve adequate benefit, and the side effects of AA are seen in almost all subjects who take the medicines.
42
Patient Safety Culture Bundle for CEOs and Senior Leaders
TL;DR: A patient safety culture bundle for CEOs and senior healthcare leaders is developed based on a set of evidence-based practices that must be applied collectively to establish and sustain a culture of quality and safety in order to deliver safe care.
Disparities in Health Care Coverage Among U.S. Born and Mexican/Central American Born Labor Workers in the U.S.
TL;DR: Using data from the 2010–2015 National Health Interview Survey, logistic regression models were employed to examine health insurance coverage and covariates among U.S. and Mexican/Central American (M/CA) born labor workers living in the U.s.
7
Patient Engagement in a Large-Scale Change Initiative: "As Safe as Possible, as Soon as Possible".
Katharina Kovacs Burns,Donna Davis,Ioana Cristina Popescu,Hina Laeeque,Sandi Kossey,Renee Misfeldt,Christopher Thrall +6 more
TL;DR: How patients were meaningfully engaged in a large-scale change initiative is illustrated, highlighting the experiences of the patient partners and organizational partners in this transformational change.
4